- 1 Creation of an Expert Curated Variant List for Clinical Genomic Test Development and Validation: A ClinGen
- 2 and GeT-RM Collaborative Project
- 3 Short Running Title (40 characters): Creation of a Curated Variant List
- 4 Emma Wilcox¹*, Steven M. Harrison¹*, Edward Lockhart², Karl Voelkerding³, Ira M. Lubin⁴, ClinGen Expert
- 5 Panels⁵ Heidi L. Rehm^{1,6}[^], Lisa Kalman⁷[^], Birgit Funke⁸[^]
- 6 *, ^ these authors contributed equally
- 7 ¹Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA
- 8 (ewilcox@broadinstitute.org, sharriso@broadinstitute.org, hrehm@broadinstitute.org)
- 9 ²Informatics and Data Science Branch, Division of Laboratory Systems, Centers for Disease Control and
- 10 Prevention, Atlanta, GA <u>coy3@cdc.gov</u>
- 11 ³Voelkerding Consulting, Salt Lake City, UT
- ⁴Quality and Safety Systems Branch, Division of Laboratory Systems, Centers for Disease Control and Prevention,
- 13 Atlanta, GA ibl0@cdc.gov
- 14 ⁵See Supplemental Table 1
- 15 ⁶Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA
- ⁷Informatics and Data Science Branch, Division of Laboratory Systems, Centers for Disease Control and
- 17 Prevention, Atlanta, GA LJK0@cdc.gov
- 18 ⁸Division of Genomic Health, Sema4, Stamford, CT
- 19

20 Corresponding Author:

- 21 Lisa Kalman, PhD
- 22 Informatics and Data Science Branch
- 23 Division of Laboratory Systems
- 24 Office of Surveillance, Epidemiology, and Laboratory Services
- 25 Centers for Disease Control and Prevention
- 26 1600 Clifton Road
- 27 Mailstop V24-3
- 28 Atlanta, GA 30333
- 29 (404) 498-2231
- 30 LKalman@cdc.gov
- 31

32 Disclosures:

- 33 The findings and conclusions in this report are those of the authors and do not necessarily represent the official
- 34 position of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry
- 35 or the National Institutes of Health. Use of trade names and commercial sources is for identification only and
- 36 does not imply endorsement by the Centers for Disease Control and Prevention, the Public Health Service, the
- 37 US Department of Health and Human Services or the National Institutes of Health.
- 38
- 39 Acknowledgements:

ClinGen is primarily funded by the National Human Genome Research Institute (NHGRI), through the following
three grants: U41HG006834, U41HG009649, U41HG009650. ClinGen also receives support for content curation
from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), through
the following three grants: U24HD093483, U24HD093486, U24HD093487.

44

45 Abstract (220 words max)

46 Modern genomic sequencing tests often interrogate large numbers of genes. Identification of appropriate 47 reference materials for development, validation studies, and guality assurance of these tests poses a significant 48 challenge for laboratories. It is difficult to develop and maintain expert knowledge to identify all variants that 49 must be validated to assure analytic and clinical validity. Additionally, it is usually not possible to procure 50 appropriate and characterized genomic DNA reference materials containing the number and scope of variants 51 required. To address these challenges, the Centers for Disease Control and Prevention's Genetic Testing 52 Reference Material Program (GeT-RM) has partnered with the Clinical Genome Resource (ClinGen) to develop a 53 publicly available list of expert curated, clinically important variants. ClinGen Variant Curation Expert Panels 54 nominated 546 variants found in 84 disease associated genes, including common pathogenic and difficult to 55 detect variants. Variant types nominated included 346 SNVs, 104 deletions, 37 CNVs, 25 duplications, 18 56 deletion-insertions, 5 inversions, 4 insertions, 2 complex rearrangements, 3 in difficult to sequence regions, and 57 2 fusions. This expert-curated variant list is a resource that provides a foundation for designing comprehensive 58 validation studies and for creating in silico reference materials for clinical genomic test development and 59 validation.

60

61 Introduction

Genetic testing has evolved from interrogating small sets of known, pathogenic variants in one or a few genes using targeted genotyping assays or Sanger sequencing to examining hundreds or thousands of genes at a time using next generation sequencing (NGS). Large gene panels are now the norm in many clinical areas, such as hereditary cancer and cardiomyopathy, and are particularly useful for disorders with locus and allelic heterogeneity. Offerings from molecular testing laboratories range from single disorder to multi-disorder
panels, the latter often allowing molecular refinement of the initial clinical diagnosis (National Institutes of
Health, Genetic Testing Registry https://www.ncbi.nlm.nih.gov/gtr/ accessed 5/6/2021).

69

70 While NGS has advanced many aspects of genetic testing, this technology has made the task of designing and 71 developing analytically and clinically valid tests more complex. This process requires deep clinical and genetic 72 expertise to understand the clinically relevant variant spectrum, and characterization of genomic context as high 73 GC content, highly homologous genes, or repetitive sequences pose challenges for most current NGS technologies .^{1, 2} When examining only one or a few well-studied genes, sufficient expertise to identify clinically 74 75 important variants can be developed easily, but this aspect of test design and development does not scale to 76 assays that examine hundreds or thousands of genes.³ Laboratories often cannot procure reference materials 77 (RMs) that encompass the scope of variants and variant types needed for NGS test development and validation 78 because the supply of available characterized genomic DNA samples from cell lines or patient samples is limited 79 and does not cover the range of genes and variants often included in NGS assays. Finally, traditional patient 80 derived RMs, such as genomic DNA from cell lines, typically contain only 1 or 2 clinically important variants per 81 sample, which can significantly increase the number of samples needed, and thus the complexity and cost of a 82 validation study when large numbers of variants need to be addressed.

83

Proper analytical validation of genomic tests and large test panels requires a combination of approaches: To ensure optimal confidence in the ability of a given technology to detect variants within a genome or subregion (e.g., exon), large numbers of variants for each clinically relevant type (SNVs, insertions, deletions, SVs) need to be analyzed. In addition, test developers should demonstrate the test's ability to detect specific clinically important variants particularly when they are technically challenging (Food and Drug Administration https://www.fda.gov/media/99208/download, accessed 3/23/2021; College of American Pathologists,

- 90 Molecular Pathology 2020 checklist <u>https://www.cap.org/</u> registration required, accessed 3/23/2021).⁴
- 91 Different types of reference materials have been created to meet these needs.
- 92
- 93 The 1000 Genomes project HapMap samples (1000 Genomes Project

94 https://www.internationalgenome.org/home; accessed 10/11/2020) were the first generation of characterized 95 genomes that were publicly available. More recently, the National Institute for Standards and Technology (NIST) 96 Genome in a Bottle project has characterized 7 publicly available genomes including NA12878 and two 97 son/mother/father trios of Ashkenazi Jewish and Han Chinese ancestry for use as reference materials (NIST https://www.nist.gov/programs-projects/genome-bottle_accessed 5/10/2021).^{5, 6} These samples have been 98 99 extensively characterized using a number of different technologies and variant calling methods covering over 100 90% of the genome. NIST has generated publicly available, high confidence benchmarking data sets that have 101 been widely used by the clinical testing community and are now also covering structural variants, and variants in highly homologous regions.⁷ In addition, Illumina produced a set of over 4.7 million phased variants from 17 102 samples of a large multigenerational pedigree.⁸ These data sets are excellent resources for establishing general 103 104 analytical performance across various variant types, but do not meet the additional need to validate specific 105 clinically important variants. Other publicly available genomic DNA samples, such as those characterized by the 106 Center for Disease Control and Prevention's Genetic Testing Reference Material Program (GeT-RM 107 https://www.cdc.gov/labquality/get-rm/index.html accessed 10/11/2020) and samples available from 108 repositories such as Coriell Institute for Medical Research (Coriell https://www.coriell.org/ accessed 5/10/2021) 109 or the American Type Culture Collection (ATCC) (ATCC <u>https://www.atcc.org/</u> accessed 5/10/2021) have 110 identified variants in some, but not all genes likely to be included in NGS tests. Although useful, none of these 111 genomic DNA samples, individually or as a group, are sufficient to represent the wide range of variants needed 112 for a thorough and comprehensive validation of an NGS assay.

114 As NGS tests have grown to include hundreds to thousands of genes, it has become technically and economically 115 impractical to rely exclusively on DNA samples for assay development and validation studies to assess assay 116 performance. Procuring sufficient reference materials containing specific variants has always been challenging 117 and can be virtually impossible for large gene panels, particularly those that span multiple disorders. In addition, 118 the commoditization of genomic testing and the availability of "off-the-shelf" gene panels have facilitated 119 implementation of genomic tests. -Well established laboratories with longstanding clinical expertise often have 120 archived DNA which can be used as reference materials for test development. In contrast, laboratories that do 121 not already have in-depth expertise in the genomic profile of the disorders included in the panels are faced with 122 a paucity of organized resources and guidance as to which clinically important variants require specific attention 123 during test development. The FDA and professional organizations including the College of American Pathologists 124 have begun to acknowledge these challenges and have responded with guidance that permits use of in silico 125 reference materials to supplement clinical test validation and operation (Food and Drug Administration 126 https://www.fda.gov/media/99208/download, accessed 3/23/2021; College of American Pathologists, Molecular Pathology 2020 checklist <u>https://www.cap.org/</u> registration required, accessed 3/23/2021). 127 128 129 In 2019, the Clinical Laboratory Improvement Advisory Committee (CLIAC) issued a recommendation to the 130 Department of Health and Human Services that the GeT-RM program should develop electronic reference 131 materials for NGS testing (https://www.cdc.gov/cliac/docs/summary/cliac0419 summary.pdf accessed 132 5/10/2021). As a first step towards this goal, GeT-RM has partnered with the Clinical Genome Resource 133 (ClinGen, https://www.clinicalgenome.org/ accessed 2/27/2021) to develop lists of expert curated, clinically 134 important variants. This publication describes these variant lists, which can be used to inform test validation 135 studies and will serve as a foundation for creating multi-variant electronic reference materials by in silico mutagenesis of laboratory generated BAM or FASTQ files.⁹⁻¹¹ 136

137

139 Methods

140 Variant nomination process

- 141 Members of 36 expert panels, including 35 of ClinGen's Variant Curation Expert Panels (VCEPs), and experts
- 142 from the CFTR2 Project were contacted in March 2020 and asked to nominate clinically important variants in the
- genes covered by the expert panels. FDA has recognized ClinGen's curation process and its resulting variant
- 144 classifications as a regulatory-grade variant database (ClinGen https://clinicalgenome.org/docs/fda-recognizes-
- 145 <u>clingen-assertions-in-clinvar-frequently-asked-questions/</u> accessed 5/10/2021; Food and Drug Administration
- 146 https://www.fda.gov/news-events/press-announcements/fda-takes-new-action-advance-development-reliable-
- 147 <u>and-beneficial-genetic-tests-can-improve-patient</u> accessed 5/10/2021). These VCEP curated, FDA recognized
- 148 variants are available via NCBI's ClinVar database and ClinGen's Evidence Repository
- 149 (https://erepo.clinicalgenome.org accessed 5/10/2021).
- 150

151 Each expert panel was asked to nominate a minimum of 10 variants per disease area, including pathogenic 152 variants that are the largest contributors to a disease as well as variants that may represent potential analytic 153 challenges to laboratories. Panels submitted their variant nominations on a standardized template from April-154 June 2020. For each variant, the panels noted if the basis for inclusion was: a) Major contributor to disease, b) 155 Analytic detection difficult, c) Filtration impact (may be inadvertently filtered out due to high allele frequency), 156 or d) Other (with explanation provided in a comment box). The panels were instructed that any reason for 157 difficult detection was appropriate including: variant type, homology issues or a high allele frequency for a lower 158 penetrant variant that might make the variant excluded by standard allele frequency filters. The ClinGen Allele 159 Registry was used to standardize nomenclature for all nominated variants and ClinVar Variation IDs and 160 associated disorders were added where available. A full list of the expert panels that contributed variants can be 161 found in Supplemental Table 1 and the full list of nominated variants can be found in Supplemental Table 2.

- 163 Not all of the ClinGen VCEPs that participated in this project have completed all four steps of the VCEP
- 164 development process required for final approval by ClinGen¹² (ClinGen
- 165 <u>https://clinicalgenome.org/docs/guidelines-for-applying-for-variant-or-gene-curation-expert-panel-status/</u>
- accessed 3/23/2021). Of the variants submitted by the panels, 38% are from expert panels with final ClinGen
- approval to submit to ClinVar as 'reviewed by expert panel', whereas 62% are from ClinGen VCEPs that were still
- 168 developing disease specifications for variant classification and were not yet fully ClinGen-approved at the time
- 169 of submission of variants to the project. VCEP status at the time of manuscript submission is shown in column B
- 170 of Supplemental table 2. Current status can be found on the ClinGen website
- 171 (https://clinicalgenome.org/working-groups/clinical-domain/ accessed 3/23/2021).
- 172

173 Limitations of variant selection process

174 Several limitations of the variant selection process should be noted. There were no explicit requirements given 175 to the expert panels in terms of the definitions of categories a, b, and c and therefore each may have used 176 slightly different definitions to select variants to nominate for this project. In addition, some expert panels may 177 have used laboratory data that is not in the public domain to identify nominated variants and this information 178 was not requested during the submission process. Furthermore, some expert panels represent genes and 179 diseases that are very rare and therefore variants may not, in general, be highly prevalent. These are not 180 considered serious limitations as these are "first-generation" variant lists, which provide an entirely new 181 resource. It is expected that this effort will continue in years to come to broaden and deepen this resource.

182

183 Results

Nominations of clinically important pathogenic or difficult to detect variants were received from 24 expert
 panels out of 36 contacted (Supplemental Table 1). Overall, 546 unique variants in 84 genes were nominated
 (Supplemental Table 2) including 22 of the 59 genes recommended by ACMG for reporting of incidental or

187	secondary findings, which are included as part of virtually all proactive genomic health tests. ¹² The nominated
188	variants are causative for a wide range of diseases many of which are commonly tested by NGS including
189	heritable cancers, inborn errors of metabolism, cardiomyopathy, diabetes, and immune disorders (Table 1). A
190	number of different variant types were nominated, including 346 SNVs, 104 deletions, 37 CNVs, 25 duplications,
191	18 deletion-insertions, 5 inversions, 4 insertions, 2 complex rearrangements, 2 fusions, and 3 variants in regions
192	defined as "difficult region to cover and map variants". The variants were nominated for a variety of reasons:
193	355 are major contributors to disease, 111 are analytically difficult to detect, 28 may have filtration impacts (be
194	inadvertently filtered out due to high allele frequency), 6 had multiple reasons for inclusion, and 46 were listed
195	as "other" or no explanation was provided (Supplemental Table 2).
196	
197	Discussion
198	Clinical laboratories in the United States are required by regulation and guided by professional or best practice
199	standards to use characterized reference materials for test development, validation and verification studies,
200	quality control and proficiency testing ¹³⁻¹⁶ (American College of Medical Genetics
201	https://www.acmg.net/PDFLibrary/Standards-Guidelines-Clinical-Molecular-Genetics.pdf , accessed 4/9/2020,

202 Washington State Legislature, <u>http://app.leg.wa.gov/WAC/default.aspx?cite=246-338-090</u>, accessed 4/9/2020,

203 College of American Pathologists <u>https://www.cap.org/</u>, accessed 4/9/2020 (registration required), New York

204 State Clinical Laboratory Evaluation Program, <u>http://www.wadsworth.org/clep</u>, accessed 4/9/2020).

205

206 Certain aspects of test development and validation, such as DNA extraction, library preparation, and sequence 207 generation will always require the use of genomic DNA from cell lines or patient samples. However, given the 208 scope of many NGS tests, it is no longer feasible to rely solely upon genomic DNA samples containing only one or 209 a few variants of interest to validate an assay that tests an entire exome or genome or many genes within a 210 large NGS panel, and novel types of reference materials are needed to enable assessment of a test's analytical 211 validity and establish adequate clinical validity.

213	The Association for Molecular Pathology and the College of American Pathologists allow the use of <i>in silico</i>
214	reference materials to supplement genomic DNA for the validation of bioinformatic pipelines (College of
215	American Pathologists, Molecular Pathology 2020 checklist <u>https://www.cap.org/</u> registration required,
216	accessed 3/23/2021). ^{4, 17-19} Specialized software ^{9, 10, 20} has been developed to edit sequence variants into BAM
217	or FASTQ files generated by the assay being validated to create customized reference materials. The software is
218	publicly available, and several companies offer this service to laboratories. The GeT-RM program is planning to
219	use these curated variants and file editing software to pilot development and use of <i>in silico</i> reference materials
220	in clinical laboratories.
221	
222	The number of variants that can be added is potentially unlimited, but care must be taken to avoid adding too
223	many variants in <i>cis</i> to the same sequence reads because it may affect alignment to the reference sequence. The
224	types of variants that can be introduced remains limited to SNVs and smaller insertions and deletions at
225	different allele fractions, although the ability to introduce CNVs is currently being developed. This approach has
226	been used successfully by the College of American Pathologists for its NGS proficiency testing challenges. ^{9, 10}
227	
228	The variant list developed by the effort presented here is available on the GeT-RM and ClinGen websites and can
229	serve as a knowledge resource to help laboratories identify important pathogenic and difficult to detect variants
230	in genes that are included in their assays, as well as a foundation for generating customized in silico reference
231	materials. GeT-RM and ClinGen will continue to collaborate to add to the current variant list and invite input
232	from the genetics community about this list and the processes used to generate it.
233	
234	
235	
236	

Gene	HGNC Gene ID	# Variants	Disorder
		nominated	
ACADVL	HGNC:92	10	Very long-chain acyl-CoA dehydrogenase
			deficiency
ACVRL1	HGNC:175	3	Hereditary hemorrhagic telangiectasia, type
			2
АРС	HGNC:583	4	Familial adenomatous polyposis
ATM	HGNC:795	6	Hereditary breast carcinoma (AD)
			Ataxia telangiectasia (AR)
BARD1	HGNC:952	5	Hereditary breast carcinoma
BRAF	HGNC:1097	1	Cardiofaciocutaneous syndrome
BRCA1	HGNC:1100	26	Breast-ovarian cancer, familial, susceptibility
			to, 1 (AD)
BRCA2	HGNC:1101	22	Breast-ovarian cancer, familial, susceptibility
			to, 2 (AD)
BRIP1	HGNC:20473	5	Familial ovarian cancer (AD)
			Fanconi anemia complementation group J
			(AR)
ВТК	HGNC:1133	10	X-linked agammaglobulinemia (XLA)
CARD11	HGNC:16393	5	CARD11 defects
CDH1	HGNC:1748	10	Hereditary diffuse gastric adenocarcinoma

CFH	HGNC:4883	5	Atypical hemolytic uremic syndrome
			(aHUS)/Thrombotic microangiopathy (TMA)
CFTR	HGNC:1884	14	Cystic fibrosis
CHEK2	HGNC:16627	5	Hereditary breast carcinoma
COL6A1	HGNC:2211	1	Congenital muscular dystrophy
CYP1B1	HGNC:2597	3	Congenital glaucoma
DCLRE1C	HGNC:17642	8	Severe combined immunodeficiency due to DCLRE1C deficiency
DES	HGNC:2770	17	Arrhythmogenic right ventricular cardiomyopathy (arrhythmogenic
			cardiomyopathy)
DICER1	HGNC:17098	7	Pleuropulmonary blastoma
DNM2	HGNC:2974	3	Centronuclear myopathy
DSC2	HGNC:3036	5	Arrhythmogenic right ventricular
			cardiomyopathy (arrhythmogenic
			cardiomyopathy)
DSG2	HGNC:3049	7	Arrhythmogenic right ventricular
			cardiomyopathy (arrhythmogenic
			cardiomyopathy)
DSP	HGNC:3052	10	Arrhythmogenic right ventricular
			cardiomyopathy (arrhythmogenic
			cardiomyopathy)

ENG	HGNC:3349	4	Hereditary hemorrhagic telangiectasia
FBN1	HGNC:3603	10	Marfan syndrome, familial thoracic aortic
			aneurysm and aortic dissection
GAA	HGNC:4065	8	Glycogen storage disease type II
GATA2	HGNC:4171	15	GATA2 deficiency with susceptibility to
			MDS/AML; GATA2 haploinsufficiency
GCK	HGNC:4195	11	Monogenic diabetes
HBA1*	HGNC:4823	4	Alpha thalassemia, Hemoglobin H disease,
			Hemoglobin Bart's hydrops fetalis
HBA2*	HGNC:4824	7	Alpha thalassemia, Hemoglobin H disease,
			Hemoglobin Bart's hydrops fetalis
HBB*	HGNC:4827	10	Sickle cell anemia, sickle cell disease
			associated with another hemoglobin
			anomaly, Beta thalassemia, Sickle cell-beta-
			thalassemia disease syndrome, Sickle cell-
			hemoglobin C disease syndrome,
			Hemoglobin C-beta-thalassemia syndrome,
			Hemoglobin C disease, Sickle cell-hemoglobin
			D disease syndrome, Hemoglobin D disease,
			Sickle cell-hemoglobin E disease syndrome,
			Hemoglobin E-beta-thalassemia syndrome,
			Hemoglobin E disease, Hemoglobin Lepore-
			beta-thalassemia syndrome

HBD*	HGNC:4829	1	Hemoglobin Lepore-beta-thalassemia
			syndrome, sickle cell-beta-thalassemia
			disease syndrome
HBQ1	HGNC:4833	1	Alpha thalassemia, Hemoglobin H disease,
			Hemoglobin Bart's hydrops fetalis
HNF1A	HGNC:11621	2	Monogenic diabetes
HNF1B	HGNC:11630	1	Monogenic diabetes
HNF4A	HGNC:5025	3	Monogenic diabetes
HRAS	HGNC:5173	1	Costello syndrome
IKBKG	HGNC:5961	6	NEMO (NFkB essential modulator) deficiency
IL2RG	HGNC:6010	10	SCID (severe combined immunodeficiency)
INS	HGNC:6081	1	Monogenic diabetes
JAK3	HGNC:6193	5	SCID (severe combined immunodeficiency)
LDLR	HGNC:6547	10	Familial hypercholesterolemia
LRBA	HGNC:1742	5	LRBA deficiency
LYST	HGNC:1968	5	Chediak-Higashi syndrome (CHS)
MAP2K1	HGNC:6840	1	Cardiofaciocutaneous syndrome
MLH1	HGNC:7127	19	Colorectal cancer, hereditary nonpolyposis,
			type 2

			Constitutional mismatch repair deficiency	
			syndrome	
MSH2	HGNC:7325	16	Lynch syndrome	
MSH6	HGNC:7329	7	Lynch syndrome	
MUTYH	HGNC:7527	2	MUTYH-related attenuated familial	
			adenomatous polyposis (AR/AD)	
МҮВРС3	HGNC:7551	16	Hypertrophic cardiomyopathy	
MYH7	HGNC:7577	6	Hypertrophic cardiomyopathy	
МҮОС	HGNC:7610	4	Open angle glaucoma	
NCF1	HGNC:7660	6	Chronic Granulomatous Disease (CGD)	
NEB	HGNC:7720	2	Nemaline myopathy	
NTHL1	HGNC:8028	1	Familial adenomatous polyposis	
РАН	HGNC:8582	17	Phenylketonuria	
PALB2	HGNC:26144	5	Hereditary breast carcinoma (AD), Fanconi	
			anemia complementation group N (AR)	
РКР2	HGNC:9024	22	Arrhythmogenic right ventricular	
			cardiomyopathy (arrhythmogenic	
			cardiomyopathy)	
PLN	HGNC:9080	4	Arrhythmogenic right ventricular	
			cardiomyopathy (arrhythmogenic	
			cardiomyopathy)	
POLD1	HGNC:9175	1	Polymerase proofreading-related	
			adenomatous polyposis	
POLE	HGNC:9177	1	Polymerase proofreading-related	
			adenomatous polyposis	

PTEN	HGNC:9588	5	PTEN hamartoma tumor syndrome
PTPN11	HGNC:9644	4	Noonan syndrome, Noonan syndrome with
			multiple lentigines
RAD51C	HGNC:9820	5	Familial ovarian cancer (AD)
RAD51D	HGNC:9823	5	Familial ovarian cancer (AD)
RAF1	HGNC:9829	1	Noonan syndrome
RAG1	HGNC:9831	7	SCID (severe combined immunodeficiency)
RUNX1	HGNC:10471	10	Familial platelet disorder with associated
			myeloid malignancy
RYR1**	HGNC:10483	17	Susceptibility to malignant hyperthermia
			(AD)
			Central core myopathy (AR/AD)
SELENON	HGNC:15999	4	Rigid spine myopathy
SHOC2	HGNC:15454	1	Noonan syndrome-like disorder with loose
			anagen hair
SMAD4	HGNC:6770	3	Juvenile polyposis/hereditary hemorrhagic
			telangiectasia syndrome
SOS1	HGNC:11187	1	Noonan syndrome
TMEM43	HGNC:28472	1	Arrhythmogenic right ventricular
	HUNC.20472	-	
			cardiomyopathy (arrhythmogenic
			cardiomyopathy)

TNNI3	HGNC:11947	1	Hypertrophic cardiomyopathy
TNNT2	HGNC:11949	2	Hypertrophic cardiomyopathy, dilated
			cardiomyopathy
TP53	HGNC:11998	10	Li-Fraumeni syndrome
TPM2	HGNC:12011	1	Nemaline myopathy
ТРМЗ	HGNC:12012	3	Nemaline myopathy
TTN	HGNC:12403	7	Distal titinopathy, tibial muscular dystrophy, hereditary myopathy with early respiratory failure
VHL	HGNC:12687	7	Von Hippel-Lindau disease
WAS	HGNC:12731	13	Wiskott- Aldrich syndrome (WAS)
WFS1	HGNC:12762	1	Monogenic diabetes
* Some variar	nts in these genes are mult	i-gene deletions o	r fusions.
**One varian	t in RYR1 was submitted b	y both the Congen	ital Myopathies and Malignant Hyperthermia
Susceptibility	VCEPs.		

238

- 239 Suppl Table 1. List of participating expert panels and names of participants
- 240 Suppl Table 2. List of variants nominated

241

242 References

Mandelker D, Schmidt RJ, Ankala A, McDonald Gibson K, Bowser M, Sharma H, Duffy E, Hegde M,
 Santani A, Lebo M, Funke B: Navigating highly homologous genes in a molecular diagnostic setting: a
 resource for clinical next-generation sequencing. Genetics in medicine : official journal of the American
 College of Medical Genetics 2016, 18:1282-1289.

- Bean LJH, Funke B, Carlston CM, Gannon JL, Kantarci S, Krock BL, Zhang S, Bayrak-Toydemir P,
 Committee ALQA: Diagnostic gene sequencing panels: from design to report-a technical standard of the
 American College of Medical Genetics and Genomics (ACMG). Genetics in medicine : official journal of
 the American College of Medical Genetics 2020, 22:453-461.
- 2513.Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, Ledbetter DH, Maglott DR, Martin252CL, Nussbaum RL, Plon SE, Ramos EM, Sherry ST, Watson MS, ClinGen: ClinGen--the Clinical Genome253Resource. The New England journal of medicine 2015, 372:2235-2242.
- 2544.Clinical and Laboratory Standards Institute: MM17 Validation and Verification of Multiplex Nucleic Acid255Assays, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2018.
- Zook JM, Catoe D, McDaniel J, Vang L, Spies N, Sidow A, Weng Z, Liu Y, Mason CE, Alexander N, Henaff E, McIntyre ABR, Chandramohan D, Chen F, Jaeger E, Moshrefi A, Pham K, Stedman W, Liang T, Saghbini M, Dzakula Z, Hastie A, Cao H, Deikus G, Schadt E, Sebra R, Bashir A, Truty RM, Chang CC, Gulbahce N, Zhao K, Ghosh S, Hyland F, Fu Y, Chaisson M, Xiao C, Trow J, Sherry ST, Zaranek AW, Ball M, Bobe J, Estep P, Church GM, Marks P, Kyriazopoulou-Panagiotopoulou S, Zheng GXY, Schnall-Levin M, Ordonez HS, Mudivarti PA, Giorda K, Sheng Y, Rypdal KB, Salit M: Extensive sequencing of seven human genomes to characterize benchmark reference materials. Scientific Data 2016, 3:160025.
- Wang Y-C, Olson ND, Deikus G, Shah H, Wenger AM, Trow J, Xiao C, Sherry S, Salit ML, Zook JM, Smith M,
 Sebra R: High-coverage, long-read sequencing of Han Chinese trio reference samples. Scientific Data
 2019, 6:91.
- Zook JM, McDaniel J, Olson ND, Wagner J, Parikh H, Heaton H, Irvine SA, Trigg L, Truty R, McLean CY, De
 La Vega FM, Xiao C, Sherry S, Salit M: An open resource for accurately benchmarking small variant and
 reference calls. Nature biotechnology 2019, 37:561-566.
- 8. Eberle MA, Fritzilas E, Krusche P, Kallberg M, Moore BL, Bekritsky MA, Iqbal Z, Chuang HY, Humphray SJ,
 Halpern AL, Kruglyak S, Margulies EH, McVean G, Bentley DR: A reference data set of 5.4 million phased
 human variants validated by genetic inheritance from sequencing a three-generation 17-member
 pedigree. Genome Res 2017, 27:157-164.
- Duncavage EJ, Abel HJ, Pfeifer JD: In Silico Proficiency Testing for Clinical Next-Generation Sequencing.
 The Journal of molecular diagnostics : JMD 2017, 19:35-42.
- Duncavage EJ, Abel HJ, Merker JD, Bodner JB, Zhao Q, Voelkerding KV, Pfeifer JD: A Model Study of In
 Silico Proficiency Testing for Clinical Next-Generation Sequencing. Archives of pathology & laboratory
 medicine 2016, 140:1085-1091.
- Li Z, Fang S, Zhang R, Yu L, Zhang J, Bu D, Sun L, Zhao Y, Li J: VarBen: Generating in Silico Reference Data
 Sets for Clinical Next-Generation Sequencing Bioinformatics Pipeline Evaluation. The Journal of
 molecular diagnostics : JMD 2021, 23:285-299.
- Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, Herman GE, Hufnagel SB, Klein TE, Korf BR,
 McKelvey KD, Ormond KE, Richards CS, Vlangos CN, Watson M, Martin CL, Miller DT, on behalf of the
 ASFMWG: Recommendations for reporting of secondary findings in clinical exome and genome
 sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical
 Genetics and Genomics. Genetics in Medicine 2017, 19:249-255.
- Chen B, Gagnon M, Shahangian S, Anderson NL, Howerton DA, Boone JD, Centers for Disease C,
 Prevention: Good laboratory practices for molecular genetic testing for heritable diseases and
 conditions. MMWR Recommendations and reports : Morbidity and mortality weekly report
 Recommendations and reports / Centers for Disease Control 2009, 58:1-37; quiz CE-31-34.
- 29014.Association for Molecular Pathology statement. Recommendations for in-house development and291operation of molecular diagnostic tests. Am J Clin Pathol 1999, 111:449-463.
- 29215.International Organization for Standardization: ISO 15189 Medical Laboratories: Requirements for293Quality and Competence. Geneva. International Organization for Standardization 2012.
- 29416.Electronic Code of Federal Regulations: The Clinical Laboratory Improvement Amendments (CLIA). Title29542 Chapter IV, Subchapter G, Part 493.

- Aziz N, Zhao Q, Bry L, Driscoll DK, Funke B, Gibson JS, Grody WW, Hegde MR, Hoeltge GA, Leonard DG,
 Merker JD, Nagarajan R, Palicki LA, Robetorye RS, Schrijver I, Weck KE, Voelkerding KV: College of
 American Pathologists' laboratory standards for next-generation sequencing clinical tests. Archives of
 pathology & laboratory medicine 2015, 139:481-493.
- Roy S, Coldren C, Karunamurthy A, Kip NS, Klee EW, Lincoln SE, Leon A, Pullambhatla M, Temple-Smolkin
 RL, Voelkerding KV, Wang C, Carter AB: Standards and Guidelines for Validating Next-Generation
 Sequencing Bioinformatics Pipelines: A Joint Recommendation of the Association for Molecular
 Pathology and the College of American Pathologists. The Journal of molecular diagnostics : JMD 2018,
 20:4-27.
- Santani A, Simen BB, Briggs M, Lebo M, Merker JD, Nikiforova M, Vasalos P, Voelkerding K, Pfeifer J,
 Funke B: Designing and Implementing NGS Tests for Inherited Disorders: A Practical Framework with
 Step-by-Step Guidance for Clinical Laboratories. The Journal of molecular diagnostics : JMD 2019,
 21:369-374.
- Patil SA, Mujacic I, Ritterhouse LL, Segal JP, Kadri S: insiM: in silico Mutator Software for Bioinformatics
 Pipeline Validation of Clinical Next-Generation Sequencing Assays. The Journal of molecular diagnostics :
 JMD 2019, 21:19-26.